California is currently home to 5600 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee
Recruiting
The primary objective of this study is to obtain evidence of the effectiveness of Cryopreserved Osteochondral Allograft Core in the treatment of osteochondral lesions on the femoral condyle.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
01/29/2025
Locations: Cedars-Sinai Kerlan Jobe Institute, Los Angeles, California
Conditions: Osteochondral Defect
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
Recruiting
The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of California, San Francisco, California
Conditions: Prostate Cancer, Prostate Cancer Metastatic
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruiting
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Exelixis Clinical Site #2, Fullerton, California
Conditions: Head and Neck Squamous Cell Carcinoma
A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS)
Recruiting
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab in adults with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: City of Hope, Duarte, California
Conditions: Solid Tumor, Adult
Feasibility of Acquiring Hyperpolarized Imaging in Patients with Meningioma
Recruiting
This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Meningioma
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Recruiting
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of California, San Diego, San Diego, California
Conditions: Metastatic Breast Cancer, Lobular Breast Carcinoma
Minimally Displaced Femoral Neck Fracture Pilot Study
Recruiting
The goal of this randomized pilot study is to assess feasibility of the trial and to collect information to inform the design of a definitive trial. Adult patients ages 60 years or older with a low-energy minimally displaced femoral neck fracture (FNF) treated with surgery will be eligible to participate in the study. Patients will be randomized to one of two treatment groups, hip arthroplasty or internal fixation. Participants will be followed for 1 year.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/29/2025
Locations: University of Southern California, Los Angeles, California
Conditions: Femoral Neck Fractures
International Multicentric Observational Study to Characterize Subpopulations of Patients with Autism Spectrum Disorder
Recruiting
To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
01/29/2025
Locations: California Neuroscience Research, Sherman Oaks, California
Conditions: Autism Spectrum Disorder
Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)
Recruiting
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, and pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
Recruiting
This phase I, first-in-human trial tests the safety, side effects, and best dose of genetically modified cells called KIND T cells after lymphodepletion (a short dose of chemotherapy) in treating patients who are HLA-A\*0201-positive and have H3.3K27M-mutated diffuse midline glioma. KIND T cells are a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory into KIND T cells so they will recognize certain markers found in tumor cells. Drugs such... Read More
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
01/29/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant
Mechanisms of Resistance to PSMA Radioligand Therapy
Recruiting
This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Prostate Cancer
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children with SCN1A-Positive Dravet Syndrome
Recruiting
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1) and aged ≥6 to \<48 months (Part 2). Part 1 follows an open-label, dose-escalation design, and Part 2 is a randomized, double-blind, sham delayed-treatment control, dose-selection study.
Gender:
ALL
Ages:
Between 6 months and 47 months
Trial Updated:
01/29/2025
Locations: UCSF Benioff Children's Hospitals, San Francisco, California
Conditions: Dravet Syndrome